BRPI0410720A - quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase - Google Patents

quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase

Info

Publication number
BRPI0410720A
BRPI0410720A BRPI0410720-9A BRPI0410720A BRPI0410720A BR PI0410720 A BRPI0410720 A BR PI0410720A BR PI0410720 A BRPI0410720 A BR PI0410720A BR PI0410720 A BRPI0410720 A BR PI0410720A
Authority
BR
Brazil
Prior art keywords
pyrido
pyrimidines
compounds
formula
tyrosine kinase
Prior art date
Application number
BRPI0410720-9A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Jinshan Chen
Richard Damian Connell
John Charles Kath
Goss Stryker Kauffman
Blaise Scott Lippa
Joel Morris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0410720A publication Critical patent/BRPI0410720A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"QUINAZOLINAS E PIRIDO¢3.4-D!PIRIMIDINAS COMO INIBIDORES DO RECEPTOR DE TIROSINA CINASE". A invenção refere-se a compostos de fórmula 1 e a seus sais, pró-fármacos e solvatos farmaceuticamente aceitáveis, em que R¬ 1¬, R¬ 3¬, R¬ 4¬, R¬ 11¬, N, Z, A, m e p são como definido aqui. A invenção também se refere a métodos de tratamento de crescimento celular anormal em mamíferos por administração dos compostos de fórmula (I) e com composições farmacêuticas para tratar tais distúrbios os quais contêm os compostos de fórmula (I). A invenção também refere-se a métodos de preparar os compostos de fórmula (I).
BRPI0410720-9A 2003-05-27 2004-05-17 quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase BRPI0410720A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47381703P 2003-05-27 2003-05-27
PCT/IB2004/001687 WO2004106308A1 (en) 2003-05-27 2004-05-17 Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0410720A true BRPI0410720A (pt) 2006-06-20

Family

ID=33490652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410720-9A BRPI0410720A (pt) 2003-05-27 2004-05-17 quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase

Country Status (7)

Country Link
US (1) US7585869B2 (pt)
EP (1) EP1636195A1 (pt)
JP (1) JP2007501854A (pt)
BR (1) BRPI0410720A (pt)
CA (1) CA2527017A1 (pt)
MX (1) MXPA05012839A (pt)
WO (1) WO2004106308A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) * 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
JPWO2005095419A1 (ja) * 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
CA2569016C (en) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US7423042B2 (en) * 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
MY145343A (en) * 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US20080096905A1 (en) * 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
EP1957468A2 (en) * 2005-09-06 2008-08-20 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4 - (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
US20090131420A1 (en) * 2005-10-07 2009-05-21 Pandey Surendrakumar S Novel Heterocyclic Analogs of Biphenyl Ethers
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
EP1979349B1 (en) * 2005-12-21 2010-07-28 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US7776857B2 (en) * 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
CA2806332C (en) * 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
CN104203242B (zh) * 2012-04-04 2017-03-15 杭州德润玉成生物科技有限公司 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
US9550738B2 (en) * 2012-05-14 2017-01-24 Hangzhouderenyucheng Biotechnology Ltd Bicyclic compounds as kinases inhibitors
CA2787472A1 (en) * 2012-08-22 2014-02-22 Pharmascience Inc. Protein kinase inhibitors
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CA2902132C (en) 2013-02-21 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2910226T3 (es) 2014-09-17 2022-05-12 Celgene Quanticel Res Inc Inhibidores de desmetilasa de histonas
EP3350181B1 (en) * 2015-09-02 2023-11-01 The Regents of The University of California Her3 ligands and uses thereof
SG11201805286RA (en) * 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
WO2021179274A1 (en) * 2020-03-13 2021-09-16 Suzhou Zanrong Pharma Ltd. ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CA3267358A1 (en) * 2022-04-05 2025-03-22 Voronoi Inc. Heteroaryl derivatives for the treatment of her2-related diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) * 1994-11-12 1997-12-01 Zeneca Ltd
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA199900021A1 (ru) * 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
CA2318842A1 (en) * 1998-01-26 1999-07-29 Julie Dorothy Warrack Quinoline derivatives as antibacterials
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2384282A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
US6603005B2 (en) * 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
ES2263743T3 (es) * 2001-04-13 2006-12-16 Pfizer Products Inc. Derivados de 4-aminopiridopirimidina sustituidos con un grupo biciclico.
DE10136459A1 (de) * 2001-07-26 2003-02-13 Bosch Gmbh Robert System mit einer Werkzeugaufnahme
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
JP4776882B2 (ja) * 2002-03-30 2011-09-21 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
AU2003272029A1 (en) * 2002-11-20 2004-06-15 Koninklijke Philips Electronics N.V. Self-shielded gradient field coil for magnetic resonance imaging
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
US7585869B2 (en) 2009-09-08
EP1636195A1 (en) 2006-03-22
MXPA05012839A (es) 2006-05-17
CA2527017A1 (en) 2004-12-09
WO2004106308A1 (en) 2004-12-09
JP2007501854A (ja) 2007-02-01
US20040242604A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
BRPI0410720A (pt) quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BRPI0713555A2 (pt) ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
BRPI0913580B8 (pt) compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos
MXPA05000715A (es) Inhibidores novedosos de cinasas.
CZ30697A3 (en) Substituted quinazoline derivatives, process of their preparation and pharmaceutical composition containing thereof
BRPI0313942C1 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0713923B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos
BRPI0514537A (pt) compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
BRPI0520812A2 (pt) método para preparar um composto de quinolina 4-substituìda, e, composto
BRPI0108841B8 (pt) derivado de pirimidina, processo para prepapar o mesmo, e composição farmacêutica
BRPI0417478A (pt) 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
NZ594353A (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
AU4483000A (en) Inhibitors of c-jun n-terminal kinases (jnk)
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.